home / stock / aplt / aplt news


APLT News and Press, Applied Therapeutics Inc. From 11/18/21

Stock Information

Company Name: Applied Therapeutics Inc.
Stock Symbol: APLT
Market: NYSE
Website: appliedtherapeutics.com

Menu

APLT APLT Quote APLT Short APLT News APLT Articles APLT Message Board
Get APLT Alerts

News, Short Squeeze, Breakout and More Instantly...

APLT - Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poste...

APLT - Applied Therapeutics EPS beats by $0.01

Applied Therapeutics (NASDAQ:APLT): Q3 GAAP EPS of -$1.09 beats by $0.01. Cash and cash equivalents of $70.21M. Press Release For further details see: Applied Therapeutics EPS beats by $0.01

APLT - Applied Therapeutics Reports Third Quarter 2021 Financial Results

Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- App...

APLT - Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

Substantial and significant reduction in sorbitol Company plans to initiate registrational trial by end of 2021 Company to host conference call and webcast today at 8:30 a.m. ET NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), ...

APLT - Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters Baseline galactitol levels clearly correlated with baseline clinical functional outcomes NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, ...

APLT - Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids

Substantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric Galactosemia patients NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Therap...

APLT - WB, MMAT and MRIN among mid-day movers

Gainers: Support.com SPRT +173%. NeuroMetrix (NASDAQ:NURO) +90%. Navios Maritime Acquisition NNA +56%. Vinco Ventures (NASDAQ:BBIG) +49%. Aterian (NASDAQ:ATER) +31%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Gambling.com Group GAMB +29%. Bill.com BILL +28%. Meta Mate...

APLT - NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers

Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...

APLT - Applied Therapeutics Reports Second Quarter 2021 Financial Results

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeuti...

APLT - Applied Therapeutics Added to Russell Microcap® Index

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company ha...

Previous 10 Next 10